methocarbamol Side Effects
Also known as: Robaxin
Analysis of 21,191 adverse event reports submitted to the FDA from 2004 to 2025.
Total Reports
21,191
Death-Related
1,643
7.8% of reports
Hospitalizations
6,345
29.9% of reports
Top Indication
Product Used For Unknown Indication
Most Reported Adverse Reactions
Who Reports Side Effects
Gender Distribution
Age Distribution
Reporting Trend by Year
Reactions in Death Reports
Top reactions reported in 1,643 reports where death was an outcome. These are voluntarily reported and do not establish causation.
| Reaction | Reports |
|---|---|
| DEATH | 528 |
| COMPLETED SUICIDE | 323 |
| TOXICITY TO VARIOUS AGENTS | 169 |
| CARDIAC ARREST | 132 |
| CARDIO-RESPIRATORY ARREST | 109 |
| PNEUMONIA | 83 |
| DYSPNOEA | 80 |
| RESPIRATORY ARREST | 73 |
| RENAL FAILURE | 72 |
| FALL | 69 |
| ACUTE KIDNEY INJURY | 61 |
| HYPERTENSION | 61 |
| OVERDOSE | 60 |
| ANXIETY | 56 |
| FATIGUE | 56 |
| SEPSIS | 56 |
| BACK PAIN | 54 |
| CHRONIC KIDNEY DISEASE | 54 |
| PAIN | 52 |
| CONFUSIONAL STATE | 48 |
Reactions in Hospitalization Reports
Top reactions in 6,345 reports where hospitalization was an outcome.
| Reaction | Reports |
|---|---|
| FALL | 588 |
| PAIN | 534 |
| NAUSEA | 509 |
| PNEUMONIA | 470 |
| DYSPNOEA | 466 |
| FATIGUE | 434 |
| DIARRHOEA | 378 |
| DRUG INEFFECTIVE | 376 |
| HEADACHE | 365 |
| VOMITING | 365 |
| BACK PAIN | 361 |
| HYPERTENSION | 347 |
| ANXIETY | 332 |
| ASTHENIA | 320 |
| ARTHRALGIA | 301 |
| PAIN IN EXTREMITY | 300 |
| DEPRESSION | 297 |
| DIZZINESS | 295 |
| OFF LABEL USE | 287 |
| PYREXIA | 276 |
Nearby — Related Medications
What the FAERS Data Reveals About methocarbamol Side Effects
The FDA Adverse Event Reporting System (FAERS) contains 21,191 voluntary reports linked to methocarbamol and its brand equivalents (Robaxin), spanning 2004 through 2025. Of those, 1,643 (7.8%) listed death as an outcome and 6,345 (29.9%) involved hospitalization. The most common indication reported alongside adverse events was Product Used For Unknown Indication.
Demographic breakdowns help contextualize who is being exposed to the drug. Of reports with known sex, 70% were female and 30% male; age distribution skews toward 45-64, with 6,430 reports in that bracket. The single most reported reaction is pain with 1,639 submissions, followed by nausea and fatigue.
FAERS is a signal-detection tool, not a scorecard. Reports are voluntary, and a single case may list multiple suspect drugs, so numbers above should not be read as incidence rates or per-patient risk. Widely prescribed drugs naturally accumulate more reports than niche therapies even when individual risk is low. These aggregates are useful for spotting patterns that merit further pharmacovigilance, not for choosing between medications. This page is for educational reference only and is not medical advice — speak with a licensed clinician about any side-effect concerns.
Read our methodology — how this data is sourced, computed, and verified.